MDxHealth SA

About MDxHealth SA

Mdxhealth is a company focused on improving the earlier detection of aggressive prostate cancer and urologic diseases through personalized molecular diagnostic solutions. Their mission is to advance precision prostate cancer diagnostics, from risk assessment to diagnosis and treatment decisions, impacting over 350,000 patients and providing accessible and affordable testing.

Products & Services

Select mdx:Helps physicians determine if a patient is at higher or lower risk for prostate cancer and identifies men who can safely avoid biopsy.

Confirm mdx:Addresses prostate biopsy sampling error and the false-negative biopsy dilemma by detecting molecular changes in benign tissue to identify risk of clinically significant prostate cancer.

Genomic Prostate Score (GPS):A genomic assay for men with low-, intermediate-, and high-risk localized prostate cancer to guide treatment decisions, providing personalized insights into tumor aggressiveness.

Resolve mdx:Combines a highly sensitive assay with ASTX™ to help providers select the right treatment for patients with UTI symptoms, also offering at-home collection for UTI and STI testing.

ExoDx Prostate Test (pending acquisition):A non-invasive, no DRE solution to enhance clinical value in prostate cancer diagnostics.

Specialties

Precision Prostate Cancer Diagnostics Urologic Diseases Molecular Diagnostic Solutions Genomic Testing Urinary Tract Infection (UTI) Testing

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Registered Public Offering T: - FT: Registered Public Offering	A: 40000000 MR: - FA: 40.0 million FAN: 40000000	D: 2024-09-25 FD: 2024-09-25	2 investors
2	RT: Public Offering T: - FT: Public Offering	A: 40000000 MR: - FA: 40.0 million FAN: 40000000	D: 2024-09-25 FD: 2024-09-25	1 investors
3	RT: Registered Public Offering T: - FT: Registered Public Offering	A: 40000000 MR: - FA: USD 40.0 million FAN: 40000000	D: 2023-02-03 FD: 2023-02-03	4 investors

Registered Public Offering Latest

2024-09-25

$40.0M

2 investors (Pro only)

Public Offering 2024-09-25

$40.0M

Registered Public Offering 2023-02-03

$40.0M

View 2 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

M

Michael K. McGarrity

Chief Executive Officer, Director

S

Scott McMahan

Vice President of Finance / Interim Chief Financial Officer

J

John Bellano

Chief Commercial Officer

J

Joseph Sollee

Executive Vice President of Corporate Development and General Counsel

K

Kim Leroux

Executive Vice President, Revenue Cycle Management

K

Koen Hoffman

Chairman and Independent Director, representing Ahok BV

View 11 more team members with Pro

Unlock Full Team Directory

Recent News

MDxHealth SA Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised

Mock Up

About MDxHealth SA

Products & Services

Specialties

Funding History

Growth Metrics

Team & Leadership

Recent News

MDxHealth SA Announces New Product Launch

Leadership Team Expands with Industry Veteran

Company Recognized as Industry Leader

Key Competitors

Competitor Alpha

Competitor Beta

Competitor Gamma

Competitor Delta

Company Details

Technology Stack